JP2020063241A5 - - Google Patents

Download PDF

Info

Publication number
JP2020063241A5
JP2020063241A5 JP2019185670A JP2019185670A JP2020063241A5 JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5 JP 2019185670 A JP2019185670 A JP 2019185670A JP 2019185670 A JP2019185670 A JP 2019185670A JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5
Authority
JP
Japan
Prior art keywords
conjugate
linker
tate
targeting moiety
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019185670A
Other languages
English (en)
Japanese (ja)
Other versions
JP6932389B2 (ja
JP2020063241A (ja
Filing date
Publication date
Priority claimed from JP2017500064A external-priority patent/JP6602834B2/ja
Application filed filed Critical
Publication of JP2020063241A publication Critical patent/JP2020063241A/ja
Publication of JP2020063241A5 publication Critical patent/JP2020063241A5/ja
Priority to JP2021131359A priority Critical patent/JP2021175757A/ja
Application granted granted Critical
Publication of JP6932389B2 publication Critical patent/JP6932389B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019185670A 2014-06-30 2019-10-09 標的化コンジュゲートならびにその粒子及び製剤 Expired - Fee Related JP6932389B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131359A JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019001P 2014-06-30 2014-06-30
US62/019,001 2014-06-30
US201462077487P 2014-11-10 2014-11-10
US62/077,487 2014-11-10
US201562150413P 2015-04-21 2015-04-21
US62/150,413 2015-04-21
JP2017500064A JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017500064A Division JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131359A Division JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Publications (3)

Publication Number Publication Date
JP2020063241A JP2020063241A (ja) 2020-04-23
JP2020063241A5 true JP2020063241A5 (enExample) 2020-06-11
JP6932389B2 JP6932389B2 (ja) 2021-09-08

Family

ID=55020088

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017500064A Expired - Fee Related JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤
JP2019185670A Expired - Fee Related JP6932389B2 (ja) 2014-06-30 2019-10-09 標的化コンジュゲートならびにその粒子及び製剤
JP2021131359A Pending JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017500064A Expired - Fee Related JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131359A Pending JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Country Status (15)

Country Link
US (4) US9750818B2 (enExample)
EP (1) EP3160518A4 (enExample)
JP (3) JP6602834B2 (enExample)
KR (2) KR102062025B1 (enExample)
CN (2) CN110478495A (enExample)
AU (2) AU2015284236B2 (enExample)
BR (1) BR212016030926U2 (enExample)
CA (1) CA2953371C (enExample)
IL (1) IL249647B (enExample)
MX (1) MX379365B (enExample)
PH (1) PH12017500023A1 (enExample)
RU (1) RU2695220C2 (enExample)
SG (1) SG11201610880RA (enExample)
WO (1) WO2016004048A2 (enExample)
ZA (1) ZA201608432B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015350A1 (en) 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
US9533054B2 (en) * 2013-03-11 2017-01-03 Shanghai Jiao Tong University Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
CN110478495A (zh) 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
CN107708676A (zh) * 2015-06-30 2018-02-16 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
SG10201912394VA (en) * 2015-07-15 2020-02-27 Celator Pharmaceuticals Inc Improved nanoparticle delivery systems
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
CA3014406A1 (en) 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia,and hormone-related tumors
WO2017161096A1 (en) * 2016-03-16 2017-09-21 Tarveda Therapeutics, Inc. Antibody mimic conjugates and particles
WO2017180834A1 (en) * 2016-04-13 2017-10-19 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
WO2017210246A2 (en) * 2016-05-31 2017-12-07 Tarveda Therapeutics, Inc. Penicillamine conjugates and particles and formulations thereof
EP3507295A1 (en) 2016-08-31 2019-07-10 Mireca Medicines GmbH New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
JP2019532091A (ja) * 2016-10-28 2019-11-07 ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｓｓｔｒ標的化コンジュゲートおよび粒子ならびにその製剤
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
BR112020000506A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
JP2020532505A (ja) * 2017-08-25 2020-11-12 エヌエーエル ファーマシューティカル グループ リミティド 薬剤の送達のための組成物および方法
AU2018354364A1 (en) * 2017-10-27 2020-05-07 Tva (Abc), Llc SSTR-targeted conjugates and formulations thereof
EP3723811A4 (en) * 2017-12-14 2021-09-01 Tarveda Therapeutics, Inc. TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
JP2021525766A (ja) * 2018-06-01 2021-09-27 ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 併用療法
CN109124096B (zh) * 2018-08-23 2021-08-06 广州百隆威尔精密五金制品有限公司 一种升降橱柜
CN111433188B (zh) * 2018-12-17 2023-08-01 荣昌生物制药(烟台)股份有限公司 一种用于抗体药物偶联物的连接子及其应用
CA3133798A1 (en) * 2019-03-18 2020-09-24 The Trustees Of Columbia University In The City Of New York Non-hydrolyzable, non-cleavable, stable linkers for precision therapeutics and uses thereof
CN109848440A (zh) * 2019-04-10 2019-06-07 燕山大学 一种钯纳米立方体的制备方法
AU2020307561A1 (en) * 2019-06-25 2022-01-20 Tva (Abc), Llc SSTR-targeted conjugates and formulations thereof
EP4106828B1 (en) 2020-02-21 2026-03-11 Tonic Medical, Inc. Polymer-encapsulated drug particles
CN112250647A (zh) * 2020-06-30 2021-01-22 浙江大学 紫杉烷类药物前体、制备方法和应用
WO2022140289A1 (en) 2020-12-21 2022-06-30 Cornell University Peptide-linked drug delivery system
WO2022174171A1 (en) 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof
US20220296514A1 (en) * 2021-03-18 2022-09-22 FormuRx Pharmaceuticals Co., Ltd. Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids
KR20230165280A (ko) * 2021-04-01 2023-12-05 알.피.쉐러 테크놀러지즈 엘엘씨 제약 제제에서 음이온 킬레이트화제로서의 인지질
IT202100014330A1 (it) * 2021-06-01 2022-12-01 The Ubeauty Com Llc Prodotto per la cura della pelle e procedimento per la sua realizzazione.
CN118005545B (zh) * 2024-01-04 2025-02-18 兰州大学 小分子抗菌肽模拟物及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
AT405906B (de) 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP1225916A1 (en) * 1999-11-01 2002-07-31 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
DE10006572A1 (de) * 2000-02-14 2001-08-23 Deutsches Krebsforsch Oligonucleotid-Konjugate
FR2824563B1 (fr) * 2001-05-10 2004-12-03 Bio Merieux Particules composites, conjugues derives, procede de preparation et applications
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
WO2003072754A2 (en) 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
US7771727B2 (en) 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
KR20140070676A (ko) * 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
WO2004080483A1 (en) 2003-03-10 2004-09-23 Mpa Technologies, Inc. Targeted agents for both photodiagnosis and photodynamic therapy
US8709998B2 (en) * 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1651162B1 (en) * 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP4318985B2 (ja) * 2003-08-21 2009-08-26 日本メジフィジックス株式会社 ソマトスタチンアナログ誘導体およびその利用
AU2006213662B2 (en) * 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
EA016577B1 (ru) * 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
BRPI0912230A2 (pt) * 2008-05-06 2017-08-22 Glaxo Group Ltd Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
EP2350118B1 (en) * 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
US9625456B2 (en) * 2009-07-02 2017-04-18 Sloan-Kettering Institute For Cancer Research Fluorescent silica-based nanoparticles
JP5892540B2 (ja) 2009-12-25 2016-03-23 国立研究開発法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
PH12012502018A1 (en) * 2010-04-30 2018-03-21 Sanwa Kagaku Kenkyusho Co Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
BR112013005711A2 (pt) * 2010-09-08 2017-06-13 Univ Texas método para tratar um tumor, mutante, molécula de ácido nucleico isolada, construção de expressão, composição, e, método para administrar uma terapia
MX2013010012A (es) * 2011-03-01 2014-04-14 Ge Healthcare Ltd Analogos de octreotato radiomarcado como trazadores de tomografia por emision de positrones.
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
EP2709666B1 (en) * 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
CN104302408B (zh) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
BR112015005878A2 (pt) * 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
CN110478495A (zh) * 2014-06-30 2019-11-22 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂

Similar Documents

Publication Publication Date Title
JP6092867B2 (ja) 担体連結しているトレプロスチニルプロドラッグ
CN108164474B (zh) 作为免疫调节剂的1,2,4-二唑衍生物
US9096642B2 (en) Therapeutic compounds for immunomodulation
JP7483776B2 (ja) 放出制御ｐｔｈ化合物の漸増用量設定
JP2020514300A5 (enExample)
US20060051315A1 (en) Polymers for delivering peptides and small molecules in vivo
RU2548905C2 (ru) Терапевтические пептиды
CN103874480A (zh) 前列环素的缓释组合物
JPWO1999061061A1 (ja) 薬物複合体
JP2010521485A5 (enExample)
RU2007131504A (ru) Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r)
JP2011184442A (ja) Ｉｌ−２１の誘導体
EP2485712A1 (en) Subcutaneous paliperidone composition
US11077082B2 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors
RU2016151859A (ru) Нацеленные конъюгаты и частицы и их составы
WO2020205996A2 (en) Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses
KR101828613B1 (ko) 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물
SK150196A3 (en) Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
JP2012530069A (ja) プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
JP7339285B2 (ja) Ｔｌｒ７ペプチドコンジュゲート
EP1372733B1 (en) Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration
US20220362278A1 (en) Renal targeting-type drug delivery carrier having excellent biodegrability
US11351137B2 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors
RU2789198C2 (ru) Композиция и способ двойного нацеливания при лечении нейроэндокринных опухолей
CA3220332A1 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors